Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 in previously treated HER2-positive locally advanced or metastatic breast cancer
2012-001628-37Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab emtansine in breast cancer (2 cohorts), sponsored by Roche. Primary endpoint: Safety and tolerability. Started Sep 2012; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-001628-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001628-37.